SSShamith A. Samarajiwa

Shamith A. Samarajiwa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shamith A. Samarajiwa has a total of 399 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    WNT/β-catenin increases 3D chromatin mobility and reorganisation during posterior cell state transitions

    by Annabelle A.M. Wurmser, Lingjun Mao, Nina Markevych, Gökçe G. Agsu, Yuze Cao, Ziwei Zhang, Mantas Jonaitis, Natasha De Winter, Benjamin D. Simons, Madapura M. Pradeepa, et al.

    Chromatin mobility, the exploration of 3D conformations by the chromatin fibre, is implicated in transcription and DNA repair, and is thought to decrease progressively as cells differentiate. Here, combining live-cell 3D single-nucleosome tracking with genomic approaches, we show that chromatin mobility instead changes in a cell-type-specific manner, increasing as pluripotent cells acquire posterior fates. This is accompanied by 3D genome reorganisation, including loss of Polycomb-associated interactions and emergence of CDX2-associated interactions. Withdrawal of posteriorising WNT/β-catenin signalling rapidly reduces chromatin mobility and partially restores Polycomb-associated chromatin interactions, while Cdx1/2/4 -null cells fail to acquire these WNT/β-catenin-dependent changes. Together, our findings establish chromatin mobility as a regulated property of cell state, with WNT/β-catenin signalling and CDX factors acting as mediators that fine-tune the sampling of 3D chromatin interactions during cell state transitions.

  • Open Access

    Non-catalytic role for MLL2 in controlling chromatin organisation and mobility during priming of pluripotent cells for differentiation

    by Maike Steindel, Oliver Davis, Katrin Neumann, Gökçe Agsu, Lingjun Mao, Andrea Kranz, Liviu Pirvan, Dwaipayan Adhya, Jorg Morf, Ziwei Zhang, et al.

    How the chromatin regulator MLL2 (KMT2B) influences cell differentiation remains poorly understood. MLL2 is the main histone 3 lysine 4 (H3K4) trimethyltransferase acting at bivalent promoters in embryonic stem cells (ESCs) and is required for ESCs to differentiate into neuroectoderm. We show here that this requirement occurs during exit from naïve pluripotency, days before neuroectoderm differentiation is impaired. Although MLL2 knockout has only a subtle effect on transcription during exit, reducing the expression of a few important neuroectodermal transcription factors, it substantially remodels chromatin architecture, disrupting 3D chromatin loops associated with bivalent promoters. The enzymatic activity of MLL2 is not needed for stabilising these loops or for neuroectoderm differentiation. This non-catalytic function of MLL2 in stabilising 3D chromatin loops has implications for lineage specification. Because MLL2 shares features with all four MLLs, chromatin tethering, rather than H3K4 methylation, may represent the primary function of MLL proteins during lineage commitment. Teaser: MLL2 must hold DNA loops together to allow cells to differentiate


  • Open Access

    KRAS G12 mutant alleles differentially control glutamine metabolism via FOXO1

    by Suzan Ber, Ming Yang, Marco Sciacovelli, Shamith Samarajiwa, Khushali Patel, Efterpi Nikitopoulou, Annie Howitt, Simon J. Cook, Ashok R. Venkitaraman, Christian Frezza, et al.

    SUMMARY: Mutations in KRAS, particularly at codon 12, are frequent in adenocarcinomas of the colon, lungs and pancreas, driving carcinogenesis by altering cell signalling and reprogramming metabolism. However, the specific mechanisms by which different KRAS G12 alleles initiate distinctive patterns of metabolic reprogramming is unclear. Using isogenic panels of colorectal cell lines harbouring the G12A, G12C, G12D and G12V heterozygous mutations and employing transcriptomics, metabolomics, and extensive biochemical validation, we demonstrate distinctive features of each allele. We also demonstrate that cells harbouring the common G12D and G12V oncogenic mutations significantly alter glutamine metabolism and nitrogen recycling through FOXO1-mediated regulation compared to parental lines. Moreover, with a combination of small molecule inhibitors targeting glutamine and glutamate metabolism, we also identify a common vulnerability that eliminates mutant cells selectively. These results highlight a previously unreported mutant-specific effect of KRAS alleles on metabolism and signalling that could be potentially harnessed for cancer therapy. In brief: Ber et al. reveal common and distinct features of oncogenic KRAS mutant isogenic cell lines. Mutant lines upregulate different nitrogen-recycling metabolic pathways and show sensitivity to combinatorial drugging of glutamine metabolism. Highlights: Different KRAS mutations trigger distinct metabolic phenotypes in colorectal cell lines Glutamine metabolism and nitrogen recycling are upregulated in KRAS mutant cells FOXO1 is a key regulator of KRAS-induced rewiring of glutamine and nitrogen metabolism Inhibition of glutamine synthetase and glutaminase selectively kills mutant KRAS lines

  • Open Access

    Early detection and diagnosis of cancer with interpretable machine learning to uncover cancer-specific DNA methylation patterns

    by Izzy Newsham, Marcin Sendera, Sri Ganesh Jammula, Shamith A Samarajiwa

    Cancer, a collection of more than two hundred different diseases, remains a leading cause of morbidity and mortality worldwide. Usually detected at the advanced stages of disease, metastatic cancer accounts for 90% of cancer-associated deaths. Therefore, the early detection of cancer, combined with current therapies, would have a significant impact on survival and treatment of various cancer types. Epigenetic changes such as DNA methylation are some of the early events underlying carcinogenesis. Here, we report on an interpretable machine learning model that can classify 13 cancer types as well as non-cancer tissue samples using only DNA methylome data, with 98.2% accuracy. We utilize the features identified by this model to develop EMethylNET, a robust model consisting of an XGBoost model that provides information to a deep neural network that can generalize to independent data sets. We also demonstrate that the methylation-associated genomic loci detected by the classifier are associated with genes, pathways and networks involved in cancer, providing insights into the epigenomic regulation of carcinogenesis.


  • Top Cited Papers
    Open Access

    Fumarate induces vesicular release of mtDNA to drive innate immunity

    by Vincent Zecchini, Vincent Paupe, Irene Herranz-Montoya, Joëlle Janssen, Inge M. N. Wortel, Jordan L. Morris, Ashley Ferguson, Suvagata Roy Chowdury, Marc Segarra-Mondejar, Ana S. H. Costa, et al.

    Mutations in fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell carcinoma1. Loss of FH in the kidney elicits several oncogenic signalling cascades through the accumulation of the oncometabolite fumarate2. However, although the long-term consequences of FH loss have been described, the acute response has not so far been investigated. Here we generated an inducible mouse model to study the chronology of FH loss in the kidney. We show that loss of FH leads to early alterations of mitochondrial morphology and the release of mitochondrial DNA (mtDNA) into the cytosol, where it triggers the activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING)–TANK-binding kinase 1 (TBK1) pathway and stimulates an inflammatory response that is also partially dependent on retinoic-acid-inducible gene I (RIG-I). Mechanistically, we show that this phenotype is mediated by fumarate and occurs selectively through mitochondrial-derived vesicles in a manner that depends on sorting nexin 9 (SNX9). These results reveal that increased levels of intracellular fumarate induce a remodelling of the mitochondrial network and the generation of mitochondrial-derived vesicles, which allows the release of mtDNAin the cytosol and subsequent activation of the innate immune response.


  • Open Access

    Accurate detection of benign and malignant renal tumor subtypes with MethylBoostER: An epigenetic marker–driven learning framework

    by Sabrina H. Rossi, Izzy Newsham, Sara Pita, Kevin Brennan, Gahee Park, Christopher G. Smith, Radoslaw P. Lach, Thomas Mitchell, Junfan Huang, Anne Babbage, et al.

    Current gold standard diagnostic strategies are unable to accurately differentiate malignant from benign small renal masses preoperatively; consequently, 20% of patients undergo unnecessary surgery. Devising a more confident presurgical diagnosis is key to improving treatment decision-making. We therefore developed MethylBoostER, a machine learning model leveraging DNA methylation data from 1228 tissue samples, to classify pathological subtypes of renal tumors (benign oncocytoma, clear cell, papillary, and chromophobe RCC) and normal kidney. The prediction accuracy in the testing set was 0.960, with class-wise ROC AUCs >0.988 for all classes. External validation was performed on >500 samples from four independent datasets, achieving AUCs >0.89 for all classes and average accuracies of 0.824, 0.703, 0.875, and 0.894 for the four datasets. Furthermore, consistent classification of multiregion samples ( N = 185) from the same patient demonstrates that methylation heterogeneity does not limit model applicability. Following further clinical studies, MethylBoostER could facilitate a more confident presurgical diagnosis to guide treatment decision-making in the future.


  • Top Cited Papers
    Open Access

    The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer

    by Saroor A. Patel, Shoko Hirosue, Paulo Rodrigues, Erika Vojtasova, Emma K. Richardson, Jianfeng Ge, Saiful E. Syafruddin, Alyson Speed, Evangelia K. Papachristou, David Baker, et al.

    Large-scale human genetic data1–3 have shown that cancer mutations display strong tissue-selectivity, but how this selectivity arises remains unclear. Here, using experimental models, functional genomics and analyses of patient samples, we demonstrate that the lineage transcription factor paired box 8 (PAX8) is required for oncogenic signalling by two common genetic alterations that cause clear cell renal cell carcinoma (ccRCC) in humans: the germline variant rs7948643 at 11q13.3 and somatic inactivation of the von Hippel-Lindau tumour suppressor (VHL)4–6. VHL loss, which is observed in about 90% of ccRCCs, can lead to hypoxia-inducible factor 2α (HIF2A) stabilization6,7. We show that HIF2A is preferentially recruited to PAX8-bound transcriptional enhancers, including a pro-tumorigenic cyclin D1 (CCND1) enhancer that is controlled by PAX8 and HIF2A. The ccRCC-protective allele C at rs7948643 inhibits PAX8 binding at this enhancer and downstream activation of CCND1 expression. Co-option of a PAX8-dependent physiological programme that supports the proliferation of normal renal epithelial cells is also required for MYC expression from the ccRCC metastasis-associated amplicons at 8q21.3-q24.3 (ref. 8). These results demonstrate that transcriptional lineage factors are essential for oncogenic signalling and that they mediate tissue-specific cancer risk associated with somatic and inherited genetic variants.


  • Open Access

    Mapping of cis-regulatory variants by differential allelic expression analysis identifies candidate causal variants and target genes of 41 breast cancer risk loci

    by Joana M. Xavier, Ramiro Magno, Roslin Russell, Bernardo P. de Almeida, Ana Jacinta-Fernandes, André Duarte, Mark Dunning, Shamith Samarajiwa, Martin O’reilly, António M. Maia, et al.

    Genome-wide association studies (GWAS) have identified hundreds of risk loci for breast cancer, but identifying causal variants and candidate target genes remains challenging. Since most risk loci fall in active gene regulatory regions, we developed a novel approach to identify variants with greater regulatory potential in the disease’s tissue of origin. Using genome-wide differential allelic expression (DAE) analysis on microarray data from 64 normal breast tissue samples, we mapped over 54K variants associated with DAE (daeQTLs). We then intersected these with GWAS data to reveal candidate risk regulatory variants and analyzed their cis-acting regulatory potential. We found 122 daeQTLs in 41 loci in active regulatory regions that are in strong linkage disequilibrium with risk-associated variants (risk-daeQTLs). We also identified 65 new candidate target genes in 29 of these loci for which no previous candidates existed. As validation, we identified and functionally characterized five candidate causal variants at the 5q14.1 risk locus targeting the ATG10 and ATP6AP1L genes, likely acting via modulation of alternative transcription and transcription factor binding. Our study demonstrates the power of DAE analysis and daeQTL mapping to understand breast cancer genetic risk, including in complex genetic regulatory landscapes. It additionally provides a genome-wide resource of variants associated with DAE for future functional studies.


  • Locus-specific induction of gene expression from heterochromatin loci during cellular senescence

    by Kosuke Tomimatsu, Dóra Bihary, Ioana Olan, Aled J Parry, Stefan Schoenfelder, Adelyne S L Chan, Guy St C Slater, Yoko Ito, Peter J Rugg-Gunn, Kristina Kirschner, et al.

    Senescence is a fate-determined state, accompanied by reorganization of heterochromatin. Although lineage-appropriate genes can be temporarily repressed through facultative heterochromatin, stable silencing of lineage-inappropriate genes often involves the constitutive heterochromatic mark, histone H3 lysine 9 trimethylation (H3K9me3). The fate of these heterochromatic genes during senescence is unclear. In the present study, we show that a small number of lineage-inappropriate genes, exemplified by the LCE2 skin genes, are derepressed during senescence from H3K9me3 regions in fibroblasts. DNA FISH experiments reveal that these gene loci, which are condensed at the nuclear periphery in proliferative cells, are decompacted during senescence. Decompaction of the locus is not sufficient for LCE2 expression, which requires p53 and C/EBPβ signaling. NLRP3, which is predominantly expressed in macrophages from an open topologically associated domain (TAD), is also derepressed in senescent fibroblasts due to the local disruption of the H3K9me3-rich TAD that contains it. NLRP3 has been implicated in the amplification of inflammatory cytokine signaling in senescence and aging, highlighting the functional relevance of gene induction from ‘permissive’ H3K9me3 regions in senescent cells.


  • Accurate differentiation of renal tumour pathological subtypes using a machine learning model of epigenetic markers

    by S. Rossi, I. Newsham, S. Pita, G. Park, R. Lach, A. Babbage, C. Smith, K. Brennan, T. Mitchell, A. Warren, et al.